4D Molecular Enrolls First Patients in Phase 3 4SIGHT Trial for DME Treatment

4D Molecular Therapeutics Inc. (FDMT) announced on September 28, 2026, that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema. The late-stage biotechnology company also reported durable two-year data from the SPECTRA trial. The announcement marks a key milestone for the company's lead gene therapy candidate targeting a major cause of vision loss. The 4SIGHT trial is a pivotal study intended to support regulatory submission. No financial terms or additional enrollment targets were disclosed in the announcement.